for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Crispr Therapeutics AG

CRSP.OQ

Latest Trade

65.36USD

Change

-0.67(-1.01%)

Volume

205,452

Today's Range

64.35

 - 

67.10

52 Week Range

22.23

 - 

74.00

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
66.03
Open
66.14
Volume
205,452
3M AVG Volume
20.43
Today's High
67.10
Today's Low
64.35
52 Week High
74.00
52 Week Low
22.23
Shares Out (MIL)
60.08
Market Cap (MIL)
3,926.62
Forward P/E
-263.76
Dividend (Yield %)
--

Next Event

Q4 2019 CRISPR Therapeutics AG Earnings Release

Latest Developments

More

CRISPR Therapeutics Announces Pricing Of Public Offering Of Common Shares

CRISPR Therapeutics Announces Proposed Public Offering Of Common Shares

CRISPR Therapeutics Reports Q3 Earnings Per Share $2.40

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Crispr Therapeutics AG

CRISPR Therapeutics AG is a Switzerland-based gene-editing company. It focuses on the development of transformative gene-based medicines for serious diseases. The Company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform, which allows for precise directed changes to genomic deoxyribonucleic acid (DNA). The Company has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient’s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The Company has business operations in London and the United Kingdom, as well as research and development operations in the United States.

Industry

Biotechnology & Drugs

Contact Info

Baarerstrasse 14

+41.41.5613277

http://www.crisprtx.com/

Executive Leadership

Rodger Novak

Chairman of the Board, President, Co-Founder

Samarth Kulkarni

Chief Executive Officer, Director

Michael John Tomsicek

Chief Financial Officer

Tony Ho

Executive Vice President - Research and Development

James R. Kasinger

General Counsel, Secretary

Key Stats

2.13 mean rating - 16 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.3K
EPS (USD)

2016

0.150

2017

-1.710

2018

-3.440

2019(E)

-0.248
Price To Earnings (TTM)
--
Price To Sales (TTM)
18.46
Price To Book (MRQ)
6.09
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-2.00
Return on Equity (TTM)
-1.82

Latest News

Latest News

IFR US ECM Weekly Wrap-up

WEEKLY TOTAL $9.6bn – IPO $993m – ABB/BLOCK $6.3bn – FOLLOW-ON $1.65bn – CB $705m Monday

IFR US ECM Calendar

Canaan (China, cryptocurrency) – $90m IPO. 10m ADSs (100% prim) at $9.00 versus $9-$11 marketing. CITI, CREN, CMBI. Nasdaq "CAN". 14 investors indicated an interest in 5% of the ADSs.

BRIEF-CRISPR Therapeutics Announces Pricing Of Public Offering Of Common Shares

* CRISPR THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON SHARES

IFR US ECM Calendar

Canaan (China, cryptocurrency) – $90m IPO. 10m ADSs (100% prim) at $9.00 versus $9-$11 marketing. CITI, CREN, CMBI. Nasdaq "CAN". 14 investors indicated an interest in 5% of the ADSs.

IFR US ECM Calendar

Amplitude Healthcare Acquisition (US, SPAC) – $100m IPO. 10m units (100% prim) at $10.00. Each unit comprises one share and one-half of a warrant. BMO, SVBL.

IFR US ECM Calendar

Amplitude Healthcare Acquisition (US, SPAC) – $100m IPO. 10m units (100% prim) at $10.00. Each unit comprises one share and one-half of a warrant. BMO, SVBL.

BRIEF-CRISPR Therapeutics Announces Proposed Public Offering Of Common Shares

* CRISPR THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON SHARES

BRIEF-CRISPR Therapeutics And Vertex Announce Data From Two Patients Treated With Gene-Editing Therapy CTX001

* CRISPR THERAPEUTICS AND VERTEX ANNOUNCE POSITIVE SAFETY AND EFFICACY DATA FROM FIRST TWO PATIENTS TREATED WITH INVESTIGATIONAL CRISPR/CAS9 GENE-EDITING THERAPY CTX001 FOR SEVERE HEMOGLOBINOPATHIES

BRIEF-CRISPR Therapeutics Reports Q3 Earnings Per Share $2.40

* CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS

BRIEF-Crispr Therapeutics And Bayer Announce Update On Casebia Therapeutics

* CRISPR THERAPEUTICS AND BAYER ANNOUNCE AN UPDATE ON CASEBIA THERAPEUTICS

BRIEF-CRISPR Therapeutics And KSQ Therapeutics Announce License Agreement To Advance Companies' Respective Cell Therapy Programs In Oncology

* CRISPR THERAPEUTICS AND KSQ THERAPEUTICS ANNOUNCE LICENSE AGREEMENT TO ADVANCE COMPANIES’ RESPECTIVE CELL THERAPY PROGRAMS IN ONCOLOGY

BRIEF-CRISPR Therapeutics And Viacyte Present Positive In Vitro Data Towards A Potential Immune-Evasive Cell Replacement Therapy For Diabetes At EASD 2019

* CRISPR THERAPEUTICS AND VIACYTE PRESENT POSITIVE IN VITRO DATA TOWARDS A POTENTIAL IMMUNE-EVASIVE CELL REPLACEMENT THERAPY FOR DIABETES AT EASD 2019 Source text for Eikon: Further company coverage:

BRIEF-Crispr Therapeutics AG May Offer And Sell From Time To Time Its Common Shares Having Aggregate Offering Price Of Up To $200 Million

* CRISPR THERAPEUTICS AG - MAY OFFER AND SELL FROM TIME TO TIME ITS COMMON SHARES HAVING AGGREGATE OFFERING PRICE OF UP TO $200 MILLION

BRIEF-Crispr Therapeutics Posts Q2 Loss Per Share Of $1.01

* CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS

GSK signs up gene-editing pioneers in drug discovery alliance

British drugmaker GSK said it has struck a research deal with the early pioneers of a prominent gene-editing technology at the University of California, in a boost to its prospects for developing new drugs.

Vertex Pharmaceuticals expands into Duchenne gene therapy with new deals

Vertex Pharmaceuticals Inc said http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20190606:nBw4wRKsa on Thursday it would acquire privately held Exonics Therapeutics for an upfront payment of $245 million and potential milestone payments...

BRIEF-Crispr Therapeutics Reports Q1 Results, Provides Business Update

* CRISPR THERAPEUTICS PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS

BRIEF-Crispr Therapeutics And Vertex Announce FDA Fast Track Designation For CTX001 For Treatment Of Beta Thalassemia

* CRISPR THERAPEUTICS AND VERTEX ANNOUNCE FDA FAST TRACK DESIGNATION FOR CTX001 FOR THE TREATMENT OF BETA THALASSEMIA Source text for Eikon: Further company coverage:

Gene therapy stocks plunge after poor trial data

Shares of U.S. gene therapy companies sank on Thursday after drugs developed by two small firms failed to show promise in separate clinical trials, underscoring the challenges in an emerging, lucrative field of biotech.

Sangamo Therapeutics shares dive after poor early-stage trial data

Sangamo Therapeutics Inc's shares sank 27 percent on Thursday after its gene-editing drug failed to show promise in an early-stage trial testing it in patients with ultra-rare disorders.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up